Delving into the Latest Updates on Medioresinol with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

MDN

Target

PGC-1α

Mechanism

PGC-1α agonists(Peroxisome proliferator-activated receptor gamma coactivator 1-alpha agonists)

Therapeutic Areas

Nervous System DiseasesCardiovascular Diseases

Active Indication

Ischemic stroke

Inactive Indication-

Originator Organization

China Pharmaceutical University

Active Organization

China Pharmaceutical University

Inactive Organization-

Drug Highest PhasePreclinical

First Approval Date-

Regulation-

Experimental and small human studies have indicated that high total adiponectin levels have beneficial cardiometabolic effects. In contrast, however, high total adiponectin levels are also associated with higher all‐cause and cardiovascular mortality in thoroughly adjusted epidemiological studies. To gain further insight into these seemingly contradictory results, we report results on total adiponectin from the indigenous Melanesian population of Kitava, Trobriand Islands, Papua New Guinea, where an apparent absence of cardiometabolic disease has been previously reported.

Methods:

Fasting levels of serum total adiponectin were measured cross‐sectionally in ≥40‐year‐old Kitavans (n = 102) and Swedish controls matched for age and sex (n = 108). Multivariable linear regression was used for the analysis of associations with total adiponectin when controlled for group, sex, smoking, hypertension and/or type 2 diabetes, age, and body mass index.

Results:

Total adiponectin was lower for Kitavans compared to Swedish controls (Median [Mdn] 4.6 μg/mL, range 1.0–206 μg/mL and Mdn 9.7 μg/mL, range 3.1–104 μg/mL, respectively, r = .64, p < .001). Lower total adiponectin was associated with Kitavan group, male sex (only in Swedish controls), smoking (only in Kitavans and Swedish controls combined), younger age (not in Swedish controls), higher BMI, lower total, low‐density lipoprotein, high‐density lipoprotein (HDL) (only in Kitavans and Swedish controls combined), and non‐HDL cholesterol, and higher anti‐PC IgG (only in Kitavans and Swedish controls combined).

Conclusion:

Total adiponectin in Kitavans was significantly lower than in Swedish controls.

Veterinary Sciences

Comparison of St. Thomas II Cardioplegia and Modified Del Nido Cardioplegia in Dogs Undergoing Mitral Valve Surgery

Article

Author: Aboshi, Yuki ; Yamada, Shusaku ; Matsuura, Katsuhiro ; Hasegawa, Mizuki ; Yaginuma, Youta ; Onuma, Yuki ; Yoshida, Tomohiko

Myocardial protection has become an essential adjunctive procedure in veterinary cardiac surgery. Del Nido cardioplegia is a good alternative to the traditional St. Thomas II (ST) cardioplegia in open heart surgery in humans. This study aims to compare intra- and postoperative results between ST cardioplegia and modified del Nido (mDN) cardioplegia in mitral valve surgery in dogs with myxomatous mitral valve disease (MMVD). This retrospective study was conducted using clinical records of 16 MMVD dogs that underwent either ST or mDN cardioplegia. We measured cardiopulmonary bypass (CPB) time, aortic cross-clamp (ACC) time, total operation time, the number of cardioplegia doses, total amount of cardioplegia, required defibrillations, in-hospital mortality and pre- and one-month postoperative echocardiographic variables. CPB (159.4 ± 16.1 vs. 210.1 ± 34.0 min), ACC (101.4 ± 7.0 vs. 136.0 ± 24.8 min) and total operation time (262.3 ± 13.1 vs. 327.0 ± 45.4 min) were significantly shorter in the mDN group (p < 0.05). The number of cardioplegia doses (3.25 ± 0.4 vs. 6.25 ± 1.2) and total amount of cardioplegia (161.3 ± 51.5 vs. 405.0 ± 185.9 mL) in the mDN group were also significantly smaller than the ST group (p < 0.05). No difference was observed in the requirement of defibrillation, in-hospital mortality and pre- and postoperative echocardiographic variables. The utilization of mDN cardioplegia was associated with shorter operative time in mitral valve surgery in dogs.

American Journal of Audiology

Benefit–Cost Analyses of Hearing Aids, Over-the-Counter Hearing Devices, and Hearing Care Services

Article

Author: Jilla, Anna Marie ; Johnson, Carole E. ; Huntington-Klein, Nick ; Baldwin, Jonathan D.

Purpose::

Limited accessibility to hearing health care threatens healthy aging in place for older adults with hearing loss. A willingness-to-pay (WTP) approach was used to determine benefits and value of prescription advanced digital technology (ADT) hearing aids, over-the-counter (OTC) hearing devices, and rehabilitative services using benefit–cost analyses.

Method::

This study was a cross-sectional survey with chart review of hearing aid users at two independent audiology practices. Seventy hearing aid users (response rate: 15.6%) provided their WTP for ADT prescription hearing aids, OTC hearing devices, and hearing rehabilitative services. Benefit–cost ratios and net social benefit were calculated using deterministic and exploratory approaches. Point estimates for benefit–cost ratios and net social benefit were derived using bootstrap sampling with replacement ( N = 5,000).

Results::

Median WTP for ADT prescription hearing aids and rehabilitative services were $2,000 and $250, respectively. WTP was lowest for OTC devices ( Mdn = $0; maximum = $500). Benefit–cost ratios and net social benefit for ADT prescription hearing aids, OTC devices, and hearing rehabilitative services favored these interventions when out-of-pocket costs remained low. Benefit–cost analyses also produced results favoring prescription ADT hearing aid intervention with costs as high as $1,530 per device.

Conclusions::

WTP results indicated that all interventions under study have a measurable consumer-perceived benefit. Results of benefit–cost analyses favored the interventions but only when costs were lower than market prices. The benefit–cost analysis results for hearing care services underscore their value when provided as part of a comprehensive rehabilitative plan that may inform future health policy changes.

100 Deals associated with Medioresinol

Login to view more data